Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Pfizer Inc. (NYSE:PFE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) were down 0.2% during trading on Friday . The company traded as low as $26 ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.53 which represents a slight increase of $0.11 or 0.42% from the prior close of $26.42. The stock opened at $26.4 and touched a low of ...

Check the time stamp on this data. Updated AI-Generated Signals for Pfizer Inc. (PFE) available here: PFE.

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Pfizer is expected to post earnings of $0.49 ...